Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Dropbox     Instagram     Google Drive     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon

SOBRE EL AUTOR **

Mi foto
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com

WORLD EMERGENCY MEDICINE SOCIETIES & RELATED

COVID-19 Inflammatory Response in Children & Adults. June 03, 2020

Search

Content:

lunes, 27 de abril de 2020

The ISCHEMIA Trial

R.E.B.E.L.EM - April 27, 2020 - By Salim Rezaie
"Paper: Maron D.J et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. NEJM 2020. PMID: 32227755.
Clinical Question: In patients with stable coronary artery disease and moderate to severe ischemia, does the addition of routine invasive therapy to optimal medical therapy (conservative) alone improve clinical outcomes?
Clinical Take Home Points:
  • There is no need to rush to the cath lab after an abnormal stress test. Optimizing medical therapy and assessing response to therapy does not place patients at greater risk. If the patient’s symptoms and angina do not improve with OMT, then an invasive strategy is appropriate.
  • In patients with stable moderate – severe coronary disease there were no clinically meaningful differences in outcomes over 4 years in those who were randomized to a conservative versus early invasive strategy.
  • Clinicians can use the results of the ISCHEMIA trial in a shared decision–making process with their patients. However, we need additional analyses that enable us to use a risk-score tool in order to provide more precise advice to patients about the relative advantages/ risks of the two strategies.
  • We should wait for a longer-term follow-up to see if any benefits of the invasive strategy become evident over time."